The DUAL PUMP Pack contains the tubing sets and manifold and is intended to perform irrigation and aspiration during anterior segment cataract surgery. It is used with the WHITESTAR SIGNATURE or WHITESTAR SIGNATURE PRO Systems ("WHITESTAR SIGNATURE System(s)"). The DUAL PUMP Pack is sterilized using ethylene oxide and is designed for single use only.

Device Description

The Dual Pump Pack, Model OPO73 is a single-use phacoemulsification pack that is an optional accessory for use with the WHITESTAR SIGNATURE Phacoemulsification Systems (K151636, K111697 and K060366), which are used to facilitate the emulsification and removal of a cataractous lens. Similar to the predicate device, the Dual Pump Pack, Model OPO73 supports peristaltic and venturi aspiration by means of a tubing interface in combination with an over-molded rear cover consisting of a diaphragm (also called the gasket with fluid channels) and a rear cover designed to generate fluid outflow from a patient's eye through aspiration tubing lines.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and supporting studies for the "Dual Pump Pack, Model OPO73":

Based on the provided document, the device described (Dual Pump Pack, Model OPO73) is a single-use phacoemulsification pack, an accessory for WHITESTAR SIGNATURE Phacoemulsification Systems, intended for irrigation and aspiration during anterior segment cataract surgery. The submission is an Abbreviated 510(k), claiming substantial equivalence to a predicate device, the FUSION Dual Pump Pack, Model OPO71 (K060366).

Acceptance Criteria and Device Performance:

The document states: "During performance testing, all anterior segment ophthalmic surgery modes that require the OPO73 functionality, including irrigation/aspiration, were conducted; all tests passed and all acceptance criteria were met."

However, specific quantitative acceptance criteria and corresponding reported device performance values are not provided in the text. The document broadly states that the device "performs as safely and as effectively as the predicate device" and that "all tests passed and all acceptance criteria were met."

1. Table of Acceptance Criteria and Reported Device Performance:

As specific quantitative criteria and performance metrics are not detailed in the provided text, a table like the one requested cannot be constructed. The document only states that:

Acceptance Criteria Category	Reported Device Performance
Functional Performance (I/A)	All tests passed; all acceptance criteria were met.
Biocompatibility	All acceptance criteria were met (referencing ISO standards).
Sterilization	All acceptance criteria were met (referencing ISO standards).
Material Evaluation (patient fluid path)	All acceptance criteria were met.
Risk Management	Compliant with ISO 14971:2007.

2. Sample Size Used for the Test Set and Data Provenance:

The document mentions "design verification and validation testing, which include parametric measurements testing and irrigation and aspiration testing." However, it does not specify the sample size used for these test sets (e.g., number of devices tested, number of in-vitro runs).

The data provenance is not explicitly stated in terms of country of origin, but it is implied to be from Abbott Medical Optics Inc., located in Santa Ana, California, USA, which submitted the 510(k). The studies conducted are non-clinical (laboratory/bench testing), not patient studies. Therefore, it is considered retrospective in the sense that it's an evaluation of the device itself rather than collecting data from live cases.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications:

This information is not applicable and not provided in the document. The studies performed are non-clinical verification and validation tests, not studies requiring expert interpretation of medical images or outcomes to establish ground truth. The "ground truth" for these engineering tests would be the established engineering specifications and performance standards.

4. Adjudication Method for the Test Set:

This information is not applicable and not provided. Adjudication methods (like 2+1 or 3+1) are typically used in clinical studies involving human interpretation or outcomes to resolve discrepancies. The studies described are bench tests with objective pass/fail criteria based on engineering specifications.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

No MRMC comparative effectiveness study was done. The document explicitly states: "No clinical studies were deemed necessary to determine the safety and effectiveness of the Dual Pump Pack - OPO73." The assessment is based on substantial equivalence to a predicate device through non-clinical testing.

6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study:

This concept is not applicable here. The device is a physical medical device (tubing and manifold for a phacoemulsification system), not an AI algorithm. Its performance is inherent in its mechanical and fluidic characteristics, not an "algorithm."

7. Type of Ground Truth Used:

The ground truth for the non-clinical tests was based on engineering specifications and performance standards. The document states that "all tests passed and all acceptance criteria were met," implying these criteria were predefined technical parameters the device had to meet to be considered safe and effective and substantially equivalent to the predicate. Compliance with various ISO and AAMI standards (e.g., ISO 14971, ISO 10993 series, ISO 11135, ANSI/AAMI ST72) also defines aspects of this "ground truth."

8. Sample Size for the Training Set:

This information is not applicable and not provided. The "Dual Pump Pack" is a hardware medical device and does not involve AI or machine learning algorithms that would require a training set.

9. How the Ground Truth for the Training Set Was Established:

This information is not applicable as there is no training set for this type of device.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract image of a stylized human figure, with three overlapping profiles suggesting a sense of community or interconnectedness. The figure is depicted in a flowing, dynamic style.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

April 27, 2016

Abbott Medical Optics Inc. Ms. Priya Viswanathan Senior Regulatory Affairs Specialist 1700 East Saint Andrew Place Santa Ana, California 92705

Re: K160236

Trade/Device Name: Dual Pump Pack Regulation Number: 21 CFR 886.4670 Regulation Name: Phacofragmentation System Regulatory Class: Class II Product Code: HQC Dated: March 23, 2016 Received: March 25, 2016

Dear Ms. Viswanathan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"

(21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Kesia Alexander

for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K160236

Device Name DUAL PUMP Pack, Model OPO73

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
× Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(K) SUMMARY 6

6.1 APPLICANT INFORMATION

Abbott Medical Optics Inc. (AMO) is submitting an Abbreviated 510(k) premarket notification for the Dual Pump Pack, Model OPO73, which is an accessory to the WHITESTAR SIGNATURE System(s); WHITESTAR SIGNATURE PRO, WHITESTAR SIGNATURE and AMO Ophthalmic Surgical Phacoemulsification Systems cleared under the premarket notifications K151636, K111697 and K060366 respectively. This 510(k) Summary is being submitted in accordance with the Medical Device Amendments of 1976, the requirements of the Safe Medical Devices Act (SMDA) of 1990 and 21 CFR 807.92.

Submitter Information:

Contact Person:

Abbott Medical Optics Inc. 1700 E. St. Andrew Place Santa Ana, CA 92799-5162, USA

Priya Viswanathan, RAC Sr. Specialist, Regulatory Affairs 1700 East St. Andrew Place Santa Ana, CA 92705 Tel: (714) 247-8670 Fax: (714) 566566-3785 Email: Priya. Viswanathan@abbott.com

Priya

Date of 510(k) Summary Preparation:

March 23, 2016.

6.2 SUBJECT DEVICE

Trade/Proprietary Name: Common Name: Classification Name: Product Code: Regulatory Class:

Dual Pump Pack - OP073 Phacoemulsification Pack, Fluidics Pack Phacofragmentation System per 21 CFR 886.4670 HQC 111

SUBSTANTIAL EQUIVALENCE SUMMARY 6.3

The Dual Pump Pack, Model OPO73, is a new optional phacoemulsification fluidios pack designed to facilitate anterior segment ophthalmic surgical procedures. The device is an optional accessory for use with the WHITESTAR SIGNATURE Phacoemulsification Systems (K151636, K111697 and K060366), which are designed for use in the surgical

{4}------------------------------------------------

setting for ophthalmologists with experience as phacoemulsification surgeons in the emulsification and removal of a cataractous lens from the eye.

The OPO73 Pack is claimed to be substantially equivalent to the following predicate:

A Predicate Device: FUSION Dual Pump Pack, Model OPO71 cleared on April 07, 2006 (K060366)
The predicate Phaco Pack, the DP (Dual Pump) Pack Disposable Tubing Set, later branded as Fusion Dual Pump Pack, Model OPO71, is designed for use in phacoemulsification procedures and provides all the tubing required for irrigation and aspiration. Both the subject device, OPO73 Pack and the predicate device, OPO71 Pack are designed for use with both the peristaltic pump and the venturi pump and share similarities in design, technology and functionality. The predicate device, Fusion Dual Pump Pack, Model OPO71 was first cleared as an accessory to the AMO Ophthalmic Surgical System under the premarket notification, K060366. The predicate device, OPO71 Pack was also cleared for use with the WHITESTAR SIGNATURE System, cleared under K111697 and WHITESTAR SIGNATURE PRO System, cleared under K151636.

Predicate Device to which Substantial Equivalence is claimed for the Dual Pump Pack, Model OP073

510(k)Number	Date of FDAClearance	Predicate Device/Accessory Name	510(k) Holder
K060366	April 07, 2006	DP Disposable Tubing Set,(Also branded as Fusion DualPump Pack, Model OP071)	Abbott MedicalOptics Inc.

6.4 DEVICE DESCRIPTION

The Dual Pump Pack, Model OPO73 is a single-use phacoemulsification pack that is an optional accessory for use with the WHITESTAR SIGNATURE Phacoemulsification Systems (K151636, K111697 and K060366), which are used to facilitate the emulsification and removal of a cataractous lens. The predicate device, the Fusion Dual Pump Pack, Model OPO71, is cleared for use with the WHITESTAR SIGNATURE Phacoemulsification Systems (K151636, K111697 and K060366) and was initially cleared for use as an accessory with the AMO Ophthalmic Surgical System under K060366. The predicate device. OPO71, Pack shares the same technology, intended use, and performance specifications as the subject device, OPO73 Pack.

TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE 6.5

Similar to the predicate device, the Dual Pump Pack, Model OPO73 supports peristaltic and venturi aspiration by means of a tubing interface in combination with an over-molded rear cover consisting of a diaphragm (also called the gasket with fluid channels) and a rear cover designed to generate fluid outflow from a patient's eye through aspiration tubing lines. The main technological characteristics in which the Dual Pump Pack, Model OPO73, is involved include irrigation and aspiration. All performance functions of the OPO73 Pack are identical to those of the predicate device, OPO71 (K060366).

{5}------------------------------------------------

The basic scientific concepts, energy source, design, intended use and FDA-recognized consensus standards used for performance testing of the Dual Pump Pack, Model OPO73, are identical to those of the predicate. FUSION Dual Pump Pack, Model OPO71 (K060366). The intended use of the Dual Pump Pack, Model OPO73 is anterior segment ophthalmic surgery, which is the same intended use as both predicate devices.

6.6 INDICATIONS FOR USE

The Indications for Use statement of the Dual Pump Pack, Model OPO73 is the followina:

SUMMARY OF PERFORMANCE DATA 6.7

The Dual Pump Pack, Model OPO73, has undergone design verification and validation testing, which include parametric measurements testing and irrigation and aspiration testing. The test results demonstrate that the subject device, the Dual Pump Pack, Model OPO73, performs as safely and as effectively as the predicate device, the FUSION Dual Pump Pack, Model OPO71. During performance testing, all anterior segment ophthalmic surgery modes that require the OPO73 functionality, including irrigation/aspiration, were conducted; all tests passed and all acceptance criteria were met.

Components of the Dual Pump Pack, Model OPO73, have indirect contact with the patient by providing a fluid path for sterile Balanced Salt Solution (BSS) to enter the eye during surgery. Verification and validation testing was completed and all acceptance criteria were met, demonstrating that the OPO73 Pack has a similar safety, effectiveness and performance profile as the predicate device. Biocompatibility, sterilization, and evaluations of the materials that comprise the patient-contacting fluid path were performed to the following standards:

Standard Number	Standard Title
ISO 14971:2007	Medical devices - Application of risk management tomedical devices
ISO 10993-1:2009	Biological evaluation of medical devices - Part 1:Evaluation and testing within a risk managementprocess
AAMI/ANSI/ISO 10993-5:2009	Biological evaluation of medical devices - Part 5:Tests for in vitro cytotoxicity
ISO 10993-7:2008	Biological evaluation of medical devices - Part 7:Ethylene oxide sterilization residuals
ISO 10993-10:2010	Biological evaluation of medical devices - Part 10:Tests for irritation and skin sensitization

{6}------------------------------------------------

Standard Number	Standard Title
ISO 10993-12:2012	Biological evaluation of medical devices - Part 12:Sample preparation and reference materials
ISO 11135:2014	Sterilization of health care products - Ethylene Oxide- Requirements for development, validation androutine control of a sterilization process for medicaldevices
ISO 11979-5:2006	Ophthalmic implants - intraocular lenses - Part 5:Biocompatibility
ISO 14937:2009	Sterilization of health care products - generalrequirements for characterization of a sterilizing agentand the development, validation and routine control ofa sterilization process for medical devices.
ANSI/AAMI ST72:2002	Bacterial endotoxins - Tests methodologies, routinemonitoring and alternatives to batch testing
ANSI/AAMI/ISO 11737-2:2009	Sterilization Of Medical Devices - MicrobiologicalMethods - Part 2: Tests Of Sterility Performed In TheDefinition, Validation And Maintenance Of ASterilization Process.

SUMMARY OF CLINICAL TESTS 6.8

No clinical studies were deemed necessary to determine the safety and effectiveness of the Dual Pump Pack - OPO73.

6.9 CONCLUSIONS

The technological characteristics that determine the functionality and performance of the Dual Pump Pack, Model OPO73, are believed to be substantially equivalent to those for the cleared FUSION Dual Pump Pack, Model OPO71 predicate device (K060366). The Dual Pump Pack, Model OPO73, will be manufactured in compliance with FDA and ISO quality system requirements. The data from the non-clinical tests demonstrate that the device is as safe and as effective and performs as safely and as effectively as the legally marketed predicate devices. Verification and validation testing demonstrate that the functional requirements and system specifications will be met prior to commercial release.

Regulation Number and Section

§ 886.4670 Phacofragmentation system.

(a)
Identification. A phacofragmentation system is an AC-powered device with a fragmenting needle intended for use in cataract surgery to disrupt a cataract with ultrasound and extract the cataract.(b)
Classification. Class II.